%0 Journal Article
%T Fibroblast Growth Factor-23 and Hypophosphatemia in Chronic Obstructive Pulmonary Disease Patients
%A Mohamed Y. Elsammak
%A 
%A Adel Attia
%A Moosa Suleman
%J Journal of Medical Biochemistry
%@ 1452-8266
%D 2012
%I 
%R 10.2478/v10011-011-0031-5
%X Impaired serum phosphate levels may contribute to respiratory muscle weakness that further negatively impacts Chronic Obstructive Pulmonary Disease (COPD) patients. Recently, Fibroblast Growth Factor 23 (FGF-23) has been shown to play an important role in the regulation of body phosphate. The current study includes 2 groups: 70 COPD patients and 34 control subjects. Blood samples were taken for a panel of routine lab tests. FGF-23 was measured using a commercially available ELISA kit. Plasma FGF-23 levels were significantly higher in the patient group compared to the control group (P=0.000). Tubular maximum absorption of phosphate was significantly reduced in COPD patients compared to the control group (P=0.04). Plasma FGF-23 negatively correlated with FEV1 and serum albumin. Elevated plasma FGF-23 levels found in COPD patients correlated with disease severity and may represent an additional factor causing low serum phosphate.
%K FGF-23
%K hypophosphatemia
%U http://versita.metapress.com/content/536t660834733v47/?p=bfc0cdac42ce4049a39bed8442296683&pi=2